• LIVING WITH CRC

    Quality of life analysis from phase II VOLFI trial compares chemotherapy regimens in RAS wild-type metastatic disease

    A prespecified secondary analysis of the phase II VOLFI AIO-KRK 0109 trial examined quality of life in patients with RAS wild-type metastatic colorectal cancer treated with mFOLFOXIRI plus panitumumab versus FOLFOXIRI. (European Journal of Cancer)